Immunovant IMVT
$31.77 −$0.75 (-2.31%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $31.51 -0.82%
Open$32.26
Prev close$32.52
Day range$31.61 – $32.77
Volume704.9K
Market cap$6.57B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Sep 2026
Revenue$0.00
Operating profit-$104.16M+21.0% YoY
Net profit-$97.25M+23.1% YoY
Diluted EPS-$0.47+35.6% YoY
Free cash flow-$83.22M+18.8% YoY
Operating cash flow-$83.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-86.5%
Return on assets-75.7%
Return on invested capital-91.2%
Current ratio7.31
Liabilities / assets13.7%
Cash & investments$722.27M
Net cash (debt)$722.27M
Income statement
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $104.16M | $160.32M | $532.90M | $159.55M | $114.36M |
| Selling and Admin Expenses | $19.14M | $17.69M | $76.24M | $17.27M | $15.44M |
| -General & Admin Expense | $19.14M | $17.69M | $76.24M | $17.27M | $15.44M |
| Research & Development | $85.01M | $142.63M | $456.66M | $142.29M | $98.92M |
| Operating Profit | -$104.16M | -$160.32M | -$532.90M | -$159.55M | -$114.36M |
| Net Non-Operating Interest Income (Expense) | $6.90M | $7.10M | $25.33M | $8.06M | $5.33M |
| Non-Operating Interest Income | $6.90M | $7.10M | $25.33M | $8.06M | $5.33M |
| Other Income (Expense) | $12,000.00 | $4,000.00 | $2.18M | $798,000.00 | -$54,000.00 |
| Other Non-Operating Income (Expenses) | $12,000.00 | $4,000.00 | $2.18M | $798,000.00 | -$54,000.00 |
| Pretax Profit | -$97.25M | -$153.22M | -$505.39M | -$150.70M | -$109.08M |
| Tax | $0.00 | $0.00 | $215,000.00 | -$2.84M | $1.55M |
| Net Profit | -$97.25M | -$153.22M | -$505.61M | -$147.86M | -$110.64M |
| Profit from Continuing Operations | -$97.25M | -$153.22M | -$505.61M | -$147.86M | -$110.64M |
| Net Income to Parent Company | -$97.25M | -$153.22M | -$505.61M | -$147.86M | -$110.64M |
| Net Income to Common Stockholders | -$97.25M | -$153.22M | -$505.61M | -$147.86M | -$110.64M |
| Basic EPS | -$0.47 | -$0.75 | -$2.77 | -$0.73 | -$0.61 |
| Diluted EPS | -$0.47 | -$0.75 | -$2.77 | -$0.73 | -$0.61 |
| Special Income (Charges) | – | – | $0.00 | – | – |
| -Less:Restructuring and Mergern & Acquisition | – | – | $0.00 | – | – |
Balance sheet
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Total Assets | $760.97M | $852.49M | $957.01M | $957.01M | $1.05B |
| Total Current Assets | $760.05M | $851.18M | $948.82M | $948.82M | $1.04B |
| Cash and Cash Equivalents & Short-Term Investments | $722.27M | $797.80M | $902.11M | $902.11M | $994.53M |
| -Cash and Cash Equivalents | $722.27M | $797.80M | $902.11M | $902.11M | $994.53M |
| Receivables | $138,000.00 | $697,000.00 | $3.95M | $3.95M | $1.64M |
| -Accounts Receivable | $138,000.00 | $697,000.00 | $1.13M | $1.13M | $1.64M |
| Other Current Assets | $37.63M | $52.68M | $42.76M | $42.76M | $46.77M |
| Total Non-Current Assets | $921,000.00 | $1.31M | $8.20M | $8.20M | $9.45M |
| Net PPE | $262,000.00 | $351,000.00 | $515,000.00 | $515,000.00 | $531,000.00 |
| Other Non-Current Assets | $659,000.00 | $961,000.00 | $7.68M | $7.68M | $8.92M |
| Total Liabilities | $104.02M | $117.10M | $104.42M | $104.42M | $66.26M |
| Total Current Liabilities | $104.02M | $117.10M | $104.42M | $104.42M | $66.26M |
| Payables | $6.79M | $10.14M | $7.72M | $7.72M | $8.62M |
| -Accounts Payable | $6.79M | $10.14M | $7.54M | $7.54M | $8.62M |
| Current Accrued Expenses | $89.89M | $101.71M | $79.87M | $79.87M | $42.34M |
| Total Non-Current Liabilities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Equity | $656.95M | $735.39M | $852.59M | $852.59M | $986.14M |
| Stockholders' Equity | $656.95M | $735.39M | $852.59M | $852.59M | $986.14M |
| Capital Stock | $20,000.00 | $20,000.00 | $20,000.00 | $20,000.00 | $20,000.00 |
| -Common Stock | $20,000.00 | $20,000.00 | $20,000.00 | $20,000.00 | $20,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.65B | $2.63B | $2.60B | $2.60B | $2.58B |
| Retained Earnings | -$2.00B | -$1.90B | -$1.75B | -$1.75B | -$1.60B |
| Gains/Losses Not Affecting Retained Earnings | $519,000.00 | $725,000.00 | $730,000.00 | $730,000.00 | $1.20M |
| -Taxes Receivable | – | – | $2.81M | $2.81M | – |
| -Gross PPE | – | – | $515,000.00 | $515,000.00 | – |
| -Due to Related Parties Current | – | – | $175,000.00 | $175,000.00 | $0.00 |
| Short-Term Debt and Capital Lease Obligation | – | – | $72,000.00 | $72,000.00 | – |
| -Current Capital Lease Obligation | – | – | $72,000.00 | $72,000.00 | – |
Cash flow
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$83.22M | -$124.41M | -$407.31M | -$95.06M | -$92.33M |
| Net cash flow from continuing operations | -$83.22M | -$124.41M | -$407.31M | -$95.06M | -$92.33M |
| Net Income from Continuing Operations | -$97.25M | -$153.22M | -$505.61M | -$147.86M | -$110.64M |
| Depreciation & Depletion & Amortization | $89,000.00 | $92,000.00 | $409,000.00 | $96,000.00 | $101,000.00 |
| Other Non-Cash Items | $27,000.00 | $27,000.00 | $99,000.00 | $26,000.00 | $25,000.00 |
| Change in Working Capital | $634,000.00 | $14.93M | $42.06M | $41.53M | $5.47M |
| -Change in Receivables | $558,000.00 | $436,000.00 | -$1.40M | -$1.82M | $319,000.00 |
| -Change in Prepaid Assets | $12.89M | -$4.95M | $8.84M | $4.31M | $2.87M |
| -Change in Payables and Accrued Expense | -$13.09M | $12.68M | $34.65M | $37.84M | $2.32M |
| -Change in Other Current Assets | $276,000.00 | $6.76M | $69,000.00 | $1.30M | -$38,000.00 |
| Financing Cash Flow | $7.88M | $20.10M | $595.76M | $3.64M | $564.60M |
| Net Cash Flow from Continuing Financing Activities | $7.88M | $20.10M | $595.76M | $3.64M | $564.60M |
| Proceeds from Stock Option Exercised | $7.88M | $20.10M | $52.07M | $3.56M | $21.00M |
| Ending Cash Balance | $722.27M | $797.80M | $902.11M | $902.11M | $994.53M |
| Net Change in Cash | -$75.33M | -$104.31M | $188.44M | -$91.43M | $472.28M |
| Beginning Cash Balance | $797.80M | $902.11M | $713.97M | $994.53M | $521.87M |
| Effect of Exchange Rate Changes | -$191,000.00 | -$4,000.00 | -$299,000.00 | -$988,000.00 | $377,000.00 |
| Free Cash Flow | -$83.22M | -$124.41M | -$407.32M | -$95.07M | -$92.33M |
| -Change in Other Current Liabilities | – | – | -$99,000.00 | – | – |
| Net cash flow from investing | – | – | -$8,000.00 | -$8,000.00 | $0.00 |
| Net Cash Flow from Continuing Investing Activities | – | – | -$8,000.00 | -$8,000.00 | $0.00 |
| Net PPE Purchase and Sale | – | – | -$8,000.00 | -$8,000.00 | $0.00 |
| Net Common Stock Issuance | – | – | $544.19M | $0.00 | – |
| Net Other Financing Charges | – | – | -$504,000.00 | $82,000.00 | – |
No comments yet — be the first to weigh in on IMVT.
Sign in to join the discussion.